Replies to post #169510 on Biotech Values

[iwfal]

GERN -

The abstract is pretty clear that they are reporting CRs and PRs for specific criteria, rather than overall CRs and PRs.

I don't think that changes anything in my post:

1) My point is that AF is picking up on a valid and important point. They aren't reporting an (the?!) important clinical parameter in this disease. And in most biotech, but especially GERN, unmentioned important parameters that they leave out are ones that don't look very good.

2) The fact that they accurately describe the parameters that they DO report does not in any way mitigate problem #1. If anything it exagerates it - because it leads people to believe they were truthful and open, when in fact they were misleading and not open.

3) Further - failing to address such weaknesses head on is dangerous to drug development.